Floatz logo

CANNABIDIVAROL

Prader-Willi Syndrome

Eric HollanderSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Prader-Willi Syndrome cohort.

Asset / SponsorPhaseRating
Genotropin
Corporacion Parc Tauli
Phase 4BBB
Oxytocin
University Hospital, Toulouse
Phase 2/3BBB
Dccr
Soleno Therapeutics, Inc.
Phase 3BB
Omnitrope
University Hospital, Toulouse
Phase 4BB
Guanfacine
Maimonides Medical Center
Phase 4BB

View all 33 →

Same molecule, other indications

CANNABIDIVAROL is also rated in:

focal epilepsyDormant
B
Indicative ·
62 / 100
View asset →
epilepsyDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →